Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.32)
# 1,439
Out of 4,654 analysts
210
Total ratings
32.12%
Success rate
-10.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FEMY Femasys | Reiterates: Buy | $12 | $1.36 | +781.06% | 12 | Oct 31, 2024 | |
| ANAB AnaptysBio | Reiterates: Buy | $55 | $21.19 | +159.56% | 4 | Oct 31, 2024 | |
| NVCR NovoCure | Reiterates: Buy | $30 | $15.62 | +92.06% | 14 | Oct 31, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Neutral | $20 | $15.84 | +26.26% | 2 | Oct 24, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $65 | $21.56 | +201.48% | 7 | Oct 24, 2024 | |
| RNAZ TransCode Therapeutics | Reiterates: Buy | $3 | $0.48 | +525.65% | 11 | Oct 24, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Buy | $30 | $11.45 | +162.01% | 13 | Oct 24, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Neutral | $6 | $2.18 | +175.23% | 13 | Oct 15, 2024 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $9 | $0.71 | +1,167.43% | 9 | Oct 9, 2024 | |
| BCTX BriaCell Therapeutics | Reiterates: Buy | $15 | $0.75 | +1,900.00% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $2.16 | +177.78% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $33 | $3.29 | +903.04% | 13 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.25 | +860.00% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $8.17 | +169.44% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.17 | +583.76% | 4 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $5.61 | +6.95% | 10 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $3.20 | +900.00% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $0.95 | +1,371.05% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $22 | $3.20 | +588.58% | 13 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.36 | +341.18% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $3.62 | +203.87% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $40 → $9 | $4.33 | +107.85% | 9 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.35 | +494.80% | 5 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $80 | $84.70 | -5.55% | 9 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.25 | - | 1 | Apr 25, 2024 |
Femasys
Oct 31, 2024
Reiterates: Buy
Price Target: $12
Current: $1.36
Upside: +781.06%
AnaptysBio
Oct 31, 2024
Reiterates: Buy
Price Target: $55
Current: $21.19
Upside: +159.56%
NovoCure
Oct 31, 2024
Reiterates: Buy
Price Target: $30
Current: $15.62
Upside: +92.06%
Arcus Biosciences
Oct 24, 2024
Reiterates: Neutral
Price Target: $20
Current: $15.84
Upside: +26.26%
Jasper Therapeutics
Oct 24, 2024
Reiterates: Buy
Price Target: $65
Current: $21.56
Upside: +201.48%
TransCode Therapeutics
Oct 24, 2024
Reiterates: Buy
Price Target: $3
Current: $0.48
Upside: +525.65%
Olema Pharmaceuticals
Oct 24, 2024
Reiterates: Buy
Price Target: $30
Current: $11.45
Upside: +162.01%
Ventyx Biosciences
Oct 15, 2024
Reiterates: Neutral
Price Target: $6
Current: $2.18
Upside: +175.23%
MiNK Therapeutics
Oct 9, 2024
Reiterates: Buy
Price Target: $9
Current: $0.71
Upside: +1,167.43%
BriaCell Therapeutics
Oct 3, 2024
Reiterates: Buy
Price Target: $15
Current: $0.75
Upside: +1,900.00%
Sep 23, 2024
Reiterates: Buy
Price Target: $6
Current: $2.16
Upside: +177.78%
Sep 20, 2024
Maintains: Buy
Price Target: $8 → $33
Current: $3.29
Upside: +903.04%
Sep 16, 2024
Reiterates: Buy
Price Target: $12
Current: $1.25
Upside: +860.00%
Sep 16, 2024
Reiterates: Buy
Price Target: $22
Current: $8.17
Upside: +169.44%
Sep 6, 2024
Reiterates: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Aug 15, 2024
Downgrades: Neutral
Price Target: $18 → $6
Current: $5.61
Upside: +6.95%
Aug 15, 2024
Reiterates: Buy
Price Target: $32
Current: $3.20
Upside: +900.00%
Aug 15, 2024
Reiterates: Buy
Price Target: $14
Current: $0.95
Upside: +1,371.05%
Aug 15, 2024
Maintains: Buy
Price Target: $23 → $22
Current: $3.20
Upside: +588.58%
Aug 12, 2024
Reiterates: Buy
Price Target: $6
Current: $1.36
Upside: +341.18%
Aug 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $3.62
Upside: +203.87%
Jul 18, 2024
Downgrades: Neutral
Price Target: $40 → $9
Current: $4.33
Upside: +107.85%
Jun 3, 2024
Reiterates: Buy
Price Target: $8
Current: $1.35
Upside: +494.80%
May 13, 2024
Maintains: Buy
Price Target: $82 → $80
Current: $84.70
Upside: -5.55%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.25
Upside: -